subgroup analysis of oak trial data supports use of atezolizumab in patients with nsclc
Published 7 years ago • 438 plays • Length 5:06Download video MP4
Download video MP3
Similar videos
-
5:45
subgroup analysis of the topaz-1 study by primary tumor location
-
1:21
assessing the impact of atezolizumab in nsclc
-
2:31
a subgroup analysis of the secombit trial
-
1:17
real-world data to account for lack of elderly patients with nsclc in clinical trials
-
39:42
subgroup analyses in early phase clinical trials - bjorn bornkamp, novartis
-
3:34
abacus trial: preoperative atezolizumab in urothelial carcinoma
-
1:50
pd-l1 agents in the treatment of nsclc
-
13:15
can they cure more types of cancers? immunitybio - ibrx stock
-
3:26
subgroup analysis from safe trial: pharmacological cardioprotective strategies for breast cancer
-
52:35
using the case study of atezolizumab development to rethink early phase oncology trial design
-
4:50
impower010: adjuvant atezolizumab improves dfs in resected stage ii-iiia nsclc
-
2:36
atezolizumab with erlotinib in combination treatment for egfr mutant nsclc
-
2:30
abacus updates: positive results for preoperative atezolizumab in bladder cancer
-
2:21
dr. kim on clinical trial eligibility criteria in lung cancer
-
1:10
the birch trial data discussed by dr peters
-
5:35
understanding clinical trials in lung cancer
-
17:13
evaluating predictive markers and subgroups in clinical trials: caution and best practices
-
3:54
guadecitabine atezolizumab in muc who have progressed after initial checkpoint inhibitor therapy
-
8:02
updates informing the management of alk-rearranged mnsclc